759842

0

BETA

img img img img
No Data Available

BETA DRUGS LIMITED Share Price Update

As of the latest trading session, BETA DRUGS LIMITED is trading at ₹1420.1, down by ₹-9.40 or -0.65% from its previous close. The stock has moved between ₹1414.00 and ₹1459.80 today. Over the past year, the stock has delivered a return of -23.82%. In the last month, it has returned 9.51%.

BETA DRUGS LIMITED performance

Today’s low Today’s high
₹ 1414.00 ₹ 1459.80
₹ 1423.40
52 week low 52 week high
₹ 990.10 ₹ 2000.00
₹ 1423.40
Open Price ₹ 1429.50
Prev. Close ₹ 1429.50
Volume (Shares) 17674.00
Total traded value ₹ 251.57
Upper Circuit ₹ 1715.40
Lower Circuit ₹ 1143.60
info

Investment Returns

Over 1 Month 9.51% Over 3 Months 35.63% Over 6 Months -16.92% Over 1 Year -23.82%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

BETA DRUGS LIMITED fundamentals


  • Market cap (Cr) 1,442.90
  • P/E Ratio (TTM) 101.10
  • Beta 0.51
  • Book Value / share 147.53
  • Return on equity 15.30%
  • EPS (TTM) 14.14
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 5.33
info icon alternate text
  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) [-]
info icon alternate text

BETA DRUGS LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 54.35
Operating Expense 50.19
Net Profit 5.33
Net Profit Margin (%) 9.80
Earnings Per Share (EPS) 5.26
EBITDA 12.67
Effective Tax Rate (%) 24.50
Particulars DEC 2025 (Values in Cr)
Revenue 50.28
Operating Expense 49.41
Net Profit 3.25
Net Profit Margin (%) 6.46
Earnings Per Share (EPS) 3.21
EBITDA 9.05
Effective Tax Rate (%) 3.56
Particulars SEP 2025 (Values in Cr)
Revenue 54.48
Operating Expense 55.10
Net Profit 1.51
Net Profit Margin (%) 2.77
Earnings Per Share (EPS) 1.50
EBITDA 7.47
Effective Tax Rate (%) 28.77
Particulars JUN 2025 (Values in Cr)
Revenue 66.32
Operating Expense 0.00
Net Profit 4.23
Net Profit Margin (%) 6.37
Earnings Per Share (EPS) 4.19
EBITDA 0.00
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 53.74
Operating Expense 53.43
Net Profit 1.39
Net Profit Margin (%) 2.58
Earnings Per Share (EPS) 1.38
EBITDA 6.96
Effective Tax Rate (%) 30.84
Particulars MAR 2026 (Values in Cr)
Revenue 225.43
Operating Expense 218.36
Net Profit 14.33
Net Profit Margin (%) 6.35
Earnings Per Share (EPS) 14.14
EBITDA 39.69
Effective Tax Rate (%) 21.30
Particulars MAR 2025 (Values in Cr)
Revenue 220.20
Operating Expense 200.98
Net Profit 15.43
Net Profit Margin (%) 7.00
Earnings Per Share (EPS) 15.29
EBITDA 33.04
Effective Tax Rate (%) 25.95
Particulars MAR 2024 (Values in Cr)
Revenue 197.62
Operating Expense 169.87
Net Profit 21.94
Net Profit Margin (%) 11.10
Earnings Per Share (EPS) 22.82
EBITDA 35.25
Effective Tax Rate (%) 25.61
Particulars MAR 2023 (Values in Cr)
Revenue 157.87
Operating Expense 133.71
Net Profit 18.82
Net Profit Margin (%) 11.92
Earnings Per Share (EPS) 19.57
EBITDA 32.24
Effective Tax Rate (%) 25.34
Particulars MAR 2022 (Values in Cr)
Revenue 124.85
Operating Expense 105.53
Net Profit 14.25
Net Profit Margin (%) 11.41
Earnings Per Share (EPS) 14.82
EBITDA 26.04
Effective Tax Rate (%) 29.36
Particulars MAR 2025 (Values in Cr)
Book Value / Share 195.25
ROE % 23.95
ROCE % 24.48
Total Debt to Total Equity 0.43
EBITDA Margin 21.10
Particulars MAR 2024 (Values in Cr)
Book Value / Share 163.43
ROE % 26.03
ROCE % 31.56
Total Debt to Total Equity 0.13
EBITDA Margin 20.75
Particulars MAR 2023 (Values in Cr)
Book Value / Share 127.82
ROE % 28.55
ROCE % 32.63
Total Debt to Total Equity 0.19
EBITDA Margin 23.72
Particulars MAR 2022 (Values in Cr)
Book Value / Share 96.05
ROE % 30.85
ROCE % 34.77
Total Debt to Total Equity 0.24
EBITDA Margin 23.64
Particulars MAR 2021 (Values in Cr)
Book Value / Share 71.37
ROE % 18.64
ROCE % 21.20
Total Debt to Total Equity 0.32
EBITDA Margin 21.74
Particulars MAR 2025 (Values in Cr)
Book Value / Share 127.83
ROE % 15.30
ROCE % 15.57
Total Debt to Total Equity 0.54
EBITDA Margin 17.08
Particulars MAR 2024 (Values in Cr)
Book Value / Share 120.67
ROE % 20.67
ROCE % 26.60
Total Debt to Total Equity 0.05
EBITDA Margin 17.84
Particulars MAR 2023 (Values in Cr)
Book Value / Share 100.12
ROE % 21.67
ROCE % 27.20
Total Debt to Total Equity 0.07
EBITDA Margin 20.42
Particulars MAR 2022 (Values in Cr)
Book Value / Share 80.57
ROE % 20.23
ROCE % 26.19
Total Debt to Total Equity 0.09
EBITDA Margin 20.86
Particulars MAR 2021 (Values in Cr)
Book Value / Share 65.96
ROE % 11.65
ROCE % 15.59
Total Debt to Total Equity 0.12
EBITDA Margin 20.04
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 147.02
Total Assets 436.23
Total Liabilities 436.23
Total Equity 197.09
Share Outstanding 1
Price to Book Ratio 14.91
Return on Assets (%) 9.72
Return on Capital (%) 12.86
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 28.63
Total Assets 254.09
Total Liabilities 254.09
Total Equity 157.11
Share Outstanding 0
Price to Book Ratio 10.22
Return on Assets (%) 14.33
Return on Capital (%) 21.67
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 19.16
Total Assets 198.42
Total Liabilities 198.42
Total Equity 122.88
Share Outstanding 0
Price to Book Ratio 6.26
Return on Assets (%) 15.48
Return on Capital (%) 22.11
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 17.32
Total Assets 157.85
Total Liabilities 157.85
Total Equity 92.34
Share Outstanding 0
Price to Book Ratio 7.02
Return on Assets (%) 15.72
Return on Capital (%) 22.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 10.42
Total Assets 117.50
Total Liabilities 117.50
Total Equity 68.61
Share Outstanding 0
Price to Book Ratio 1.82
Return on Assets (%) 9.97
Return on Capital (%) 14.08
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 141.98
Total Assets 316.52
Total Liabilities 316.52
Total Equity 129.03
Share Outstanding 1
Price to Book Ratio 14.91
Return on Assets (%) 4.87
Return on Capital (%) 6.1
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 27.19
Total Assets 170.47
Total Liabilities 170.47
Total Equity 116.01
Share Outstanding 0
Price to Book Ratio 10.22
Return on Assets (%) 12.86
Return on Capital (%) 18.34
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 17.79
Total Assets 134.04
Total Liabilities 134.04
Total Equity 96.25
Share Outstanding 0
Price to Book Ratio 6.26
Return on Assets (%) 14.03
Return on Capital (%) 18.82
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 15.58
Total Assets 110.89
Total Liabilities 110.89
Total Equity 77.46
Share Outstanding 0
Price to Book Ratio 7.02
Return on Assets (%) 12.84
Return on Capital (%) 17.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 8.26
Total Assets 86.23
Total Liabilities 86.23
Total Equity 63.41
Share Outstanding 0
Price to Book Ratio 1.82
Return on Assets (%) 8.09
Return on Capital (%) 10.37
Particulars MAR 2025 (Values in Cr)
Net Income 61.53
Cash from Operations 36.14
Cash from Investing -35.71
Cash from Financing 117.96
Net change in Cash 118.39
Free Cash Flow 73.00
Particulars MAR 2024 (Values in Cr)
Net Income 48.75
Cash from Operations 30.93
Cash from Investing -13.97
Cash from Financing -7.48
Net change in Cash 9.46
Free Cash Flow 42.54
Particulars MAR 2023 (Values in Cr)
Net Income 41.05
Cash from Operations 23.38
Cash from Investing -19.06
Cash from Financing -2.47
Net change in Cash 1.83
Free Cash Flow 41.59
Particulars MAR 2022 (Values in Cr)
Net Income 34.30
Cash from Operations 29.62
Cash from Investing -21.75
Cash from Financing -0.97
Net change in Cash 6.89
Free Cash Flow 49.05
Particulars MAR 2021 (Values in Cr)
Net Income 15.95
Cash from Operations 18.59
Cash from Investing -5.84
Cash from Financing -7.71
Net change in Cash 5.03
Free Cash Flow 24.35
Particulars MAR 2025 (Values in Cr)
Net Income 25.41
Cash from Operations 18.04
Cash from Investing -21.45
Cash from Financing 118.20
Net change in Cash 114.78
Free Cash Flow 42.48
Particulars MAR 2024 (Values in Cr)
Net Income 29.48
Cash from Operations 21.18
Cash from Investing -11.02
Cash from Financing -0.76
Net change in Cash 9.40
Free Cash Flow 27.62
Particulars MAR 2023 (Values in Cr)
Net Income 25.20
Cash from Operations 10.22
Cash from Investing -5.81
Cash from Financing -2.19
Net change in Cash 2.21
Free Cash Flow 17.13
Particulars MAR 2022 (Values in Cr)
Net Income 20.16
Cash from Operations 18.76
Cash from Investing -12.71
Cash from Financing 1.26
Net change in Cash 7.31
Free Cash Flow 28.37
Particulars MAR 2021 (Values in Cr)
Net Income 9.88
Cash from Operations 11.59
Cash from Investing -3.15
Cash from Financing -4.34
Net change in Cash 4.10
Free Cash Flow 15.03
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 35.69 14.75 1.72 273.50 23.12 40.00
BLISS GVS PHARMA LTD 424.80 34.37 3.76 4493.92 118.35 437.40
CIPLA LTD. 1398.50 27.69 3.28 112970.91 1165.55 1672.20
FERMENTA BIOTECH LIMITED 295.20 13.02 2.13 868.80 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 35.69 24.96 4.59 273.50 23.12 40.00
AMRUTANJAN HEALTH CARE LTD. 559.55 25.08 4.36 1617.69 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8671.45 113.25 24.83 21678.63 7630.00 10653.05
BLISS GVS PHARMA LTD 424.80 45.68 3.89 4493.92 118.35 437.40

BETA DRUGS LIMITED shareholding pattern

Holding
32.06%
66.73%
0.9%
0.29%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

BETA DRUGS LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1423.40 -0.42 redarrow
red-green-graph indicator
2 Bearish
14 Bullish
  • 5 Days 1393.50
  • 26 Days 1333.90
  • 10 Days 1360.80
  • 50 Days 1322.40
  • 12 Days 1354.40
  • 100 Days 1365.30
  • 20 Days 1340.60
  • 200 Days 1465.90
1429.87 PIVOT
First Support 1409.73 First Resistance 1449.63 Second Support 1389.97 Second Resistance 1469.77 Third Support 1369.83 Third Resistance 1489.53
RSI 60.44 ADX 17.86 MACD 20.48 Williams % R -13.55 Commodity Channel Index (CCI) 110.38
Date 2026-05-29 Week 18228.00 Same Day 14383.00 Month 12456.00
1 Year 0.52 3 Year 0.82
Over 1 Month
9.51% down
Over 1 Year
-23.82% down
Over 3 Months
35.63% down
Over 3 Years
27.51% down
Over 6 Months
-16.92% down
Over 5 Years
39.31% down

BETA DRUGS LIMITED Corporate Actions

Ex-Date Ex-Bonus Ratio
26 Mar 2025 26 Mar 2025 1:20

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Beta Drugs Ltd?

Answer Field

Beta Drugs Ltd share price is for NSE ₹ 1,420.10 & for BSE ₹ 0.00 as on Jun 01 2026 03:29 PM.

What is the Market Cap of Beta Drugs Ltd Share?

Answer Field

The market cap of Beta Drugs Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 01 2026 03:29 PM.

What is the 52 Week High and Low of Beta Drugs Ltd?

Answer Field

The 52 Week High and Low of Beta Drugs Ltd for NSE is ₹ 2,000.00 and ₹ 990.10 and for BSE is ₹ 0.00 and ₹ 0.00.

What is 1 year return for Beta Drugs Ltd?

Answer Field

The 1 year returns on the stock has been -23.82%.

What is the P/E Ratio of Beta Drugs Ltd Share?

Answer Field

As on Jun 01 2026 03:29 PM the price-to-earnings (PE) ratio for Beta Drugs Ltd share is 101.10.

What is the PB ratio of Beta Drugs Ltd Share?

Answer Field

As on Jun 01 2026 03:29 PM, the price-to-book (PB) ratio for Beta Drugs Ltd share is 147.53.

How to Buy Beta Drugs Ltd Share?

Answer Field

You can trade in Beta Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Beta Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Beta Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Beta Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|